SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics (AMEX:CXM) announced that positive findings from pooled by-patient analysis of the AGENT-3 and AGENT-4 Phase 2b/3 clinical trials will be published in the September 11, 2007 issue of the Journal of the American College of Cardiology (JACC) and is now available online. Among the findings reported, a pre-specified analysis showed significant improvements in multiple clinical measures of heart disease among women who received Generx™ (alferminogene tadenovec, Ad5FGF-4) as compared to women in the placebo control group. Generx is being developed as a potential treatment for men and women with myocardial ischemia (insufficient blood flow within the heart muscle) and associated angina due to coronary heart disease and represents a new therapeutic class of cardiovascular biologics. Generx is designed to promote angiogenesis, a natural process of blood vessel growth within the heart muscle, following a one-time intracoronary infusion from a standard cardiac infusion catheter. The Company recently announced that the FDA had granted Fast Track designation to Generx.
